$5.63
+1.3%Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
Flat FCF growth. Stable but not expanding—monitor for signs of business maturity or temporary headwinds.
Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
IMA • NASDAQ
| ImageneBio Inc Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||
-52.4M | -49.2M | -68.2M | -68.8M | -34.1M | -44.3M | -16.8M | -40.9M | |
328K | 490K | 1M | 751K | 544K | 300K | 243K | 422K | |
15.4M | 5.3M | 0.0 | 7.5M | 5.2M | 1.8M | 1.2M | 314K | |
8M | 1.4M | 9.1M | 1.5M | 1.2M | 12.1M | -121K | 29M | |
-19.2M | -4M | -21.7M | -15.1M | -33M | -7.8M | 63.5M | 58K | |
-47.8M | -46M | -79.7M | -74.1M | -60.3M | -37.8M | 47.9M | -11.6M | |
INVESTING ACTIVITIES | ||||||||
(0.0) | (0.0) | -414K | -1.4M | -1.8M | -766K | -316K | -305K | |
-5.2M | (0.0) | (0.0) | (0.0) | (0.0) | (3.7M) | (0.0) | (11.3M) | |
-10.4M | -88.3M | -90.1M | -216.3M | (0.0) | (0.0) | (0.0) | (0.0) | |
9.8M | 60.5M | 154.6M | 118.5M | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | -7.1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 11.3M | |
-5.8M | -34.9M | (64.1M) | -99.3M | -1.8M | (2.9M) | -316K | (11M) | |
FINANCING ACTIVITIES | ||||||||
65.8M | 0.0 | 36.9M | 0.0 | 131.3M | -57K | 0.0 | 0.0 | |
15M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
(0.0) | (0.0) | -663K | (0.0) | (0.0) | -57K | (0.0) | (0.0) | |
54.6M | 0.0 | 39.1M | 1.1M | 582K | 70K | 25K | 0.0 | |
135.5M | 0.0 | 76M | 1.1M | 131.7M | 116.2M | 16.3M | 0.0 | |
CASH FLOW SUMMARY | ||||||||
604K | 0.0 | -406K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
82.4M | -80.9M | 60M | -172.3M | 69.7M | 81.3M | 63.9M | -639K | |
12.1M | 121.2M | 59.9M | 233.1M | 163.4M | 82.1M | 18.2M | 18.8M | |
94.5M | 40.3M | 119.9M | 60.8M | 233.1M | 163.4M | 82.1M | 18.2M | |
-47.8M | -46M | -80.2M | -75.5M | -62M | -38.6M | 47.6M | -11.9M |
IMA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 16, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 13, 2026 | April 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 17, 2026 | March 12, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 10, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 10, 2026 | March 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 17, 2026 | February 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 18, 2025 | December 12, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 19, 2025 | November 19, 2025 | 2025 |
Continue your IMA research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.